How Novel mRNA Platforms Are Unlocking Durable Gene Therapies

mRNA Therapeutics

8/7/20267 min read

The clinical success of messenger RNA (mRNA) vaccines against SARS-CoV-2 cemented synthetic RNA as a transformative class of biopharmaceuticals. However, classic linear mRNA therapies possess a fundamental limitation: a very short half-life. Standard in vitro transcribed (IVT) mRNAs are degraded rapidly by cellular endo- and exonucleases, featuring a intracellular half-life often measured in hours or a few days.

While rapid decay is desirable for acute immunization or transient protein expression, chronic genetic disorders—such as hemophilia, lysosomal storage diseases, and metabolic dystrophies—require persistent, long-term protein production. Achieving this historically meant turning to viral vectors like Adeno-Associated Viruses (AAVs) or Lentiviruses. Yet viral modalities suffer from challenges including neutralizing antibody formation, genome size limits, and insertional mutagenesis risks.

To bridge this gap, a new wave of biotechnology innovators is developing durable mRNA therapeutics. By reimagining mRNA architecture, manufacturing workflows, transient enzymatic integration, and organ-targeted lipid delivery, companies are transforming RNA from a short-lived signal into a long-term therapeutic engine.

The Biological Bottleneck of mRNA Longevity

Cellular RNA degradation is an aggressive defense mechanism against foreign genetic material and a control system for gene expression. Canonical linear mRNA contains a 5′ 7-methylguanosine (m7G) cap, untranslated regions (UTRs), an open reading frame (ORF), and a 3′ poly(A) tail.

Degradation primarily occurs via two pathways:

Deadenylation-dependent decay: The CNOT complex trims the poly(A) tail, triggering 5′ decapping by DCP2 and 5' to 3' degradation by XRN1, or $3' to 5' degradation by the exosome.
Innate immune recognition: Pattern Recognition Receptors (PRRs) such as TLR3, TLR7/8, RIG-I, and MDA5 sense exogenous RNA structures, releasing type I interferons that shutdown translation and accelerate RNA clearance.

To overcome these barriers, therapeutic strategies have split into two complementary paradigms:

Structural Longevity: Engineering non-canonical RNA shapes (e.g., circular RNA or self-amplifying RNA) that physically resist exonuclease breakdown.
Genomic Integration via Transient mRNA: Using mRNA purely as a transient vector to encode sequence-specific writers, integrases, or transposases that stably modify the host genome without persistent viral capsids.

Here we cover the platforms working on genome engineering using mRNA-encoded machinery

1) Typewriter Therapeutics: Permanent Durability via mRNA-Encoded "Writers"

Typewriter Therapeutics achieves permanent therapeutic durability by using mRNA as an instructional, temporary code to write new genetic sequences directly into the host genome.

Through its Piano™ platform, Typewriter uses mRNA to encode engineered RNA-guided DNA endonucleases and reverse transcriptases (derived from prime editors and retrotransposon-based systems). Rather than relying on double-stranded breaks (DSBs) that induce unpredictable insertion-deletion mutations (indels), the mRNA-encoded writer transcribes new functional sequence directly into a targeted genomic locus using an engineered RNA template.

Because the mRNA encoding the "writer" enzyme decays within hours, the enzyme is expressed only transiently—virtually eliminating off-target cleavage risks. However, the resulting DNA rewrite in the stem cell or target organ genome is permanent, achieving lifelong therapeutic efficacy from a single administration.

Key Publications & Patents

Peer-Reviewed Reference: The conceptual mechanics of RNA-guided retrotransposition and prime editing platforms are detailed by Anzalone et al. in "Search-and-replace genome editing without double-strand breaks or donor DNA" (Nature, 2019) and subsequent studies on CRISPR-associated transposases (Klompe et al., Nature, 2019).
Patent Citation: Typewriter's proprietary system for nucleic acid insertion is detailed in WO Patent Application 2023/018920 A1 ("Compositions and methods for site-specific genomic integration using RNA-guided transcriptase platforms"), which covers structural designs of mRNA constructs encoding composite reverse-transcriptase-fusion proteins alongside target-site-seeking guide RNAs.

2) Addition Therapeutics: Non-Viral Targeted Gene Addition

Similar to Typewriter, Addition Therapeutics focuses on achieving long-term durable transgene expression, but focuses specifically on the delivery of whole therapeutic genes into safe harbors via non-viral gene insertion.

Addition Therapeutics utilizes mRNA encoding site-specific integrases and transposase systems (such as engineered piggyBac, Sleeping Beauty, or phage-derived integrases). The therapeutic gene payload is delivered alongside an mRNA transcript encoding the integration enzyme. Once translated in the cytoplasm, the enzyme translocates to the nucleus, recognizes specific genomic safe harbor sites, and inserts the therapeutic DNA payload into the host chromosome.

By using mRNA to encode the transposase or integrase rather than viral vectors:

Expression of the integration driver is transient, minimizing long-term immunogenicity and re-integration events.
Large payload genes (>10–15 kb) that exceed AAV packaging limits can be integrated stably.
Patients avoid neutralizing immunity against the vector, allowing re-dosing if initial tissue coverage is incomplete.

Key Publications & Patents

Peer-Reviewed Reference: The safety and efficiency of transient transposase delivery via mRNA for stable genomic integration was validated by Yusa et al. in "A hyperactive piggyBac transposase for mammalian applications" (Proceedings of the National Academy of Sciences, 2011) and further expanded by Hice et al. (Molecular Therapy, 2022).
Patent Citation: Addition Therapeutics' platform strategies are captured in WO Patent Application 2022/232456 A2 ("Targeted non-viral genomic integration systems and mRNA formulations thereof"), which outlines optimized mRNA sequences encoding hyperactive integrase variants that exhibit reduced off-target insertion profiles.

3) Averna Therapeutics: Tissue-Tropic LNPs & Stealth mRNA Formulations

Even the most structurally stable or enzyme-encoding mRNA will fail if it is cleared prematurely by hepatic macrophages or triggers innate cellular immunity before translation. Averna Therapeutics focuses on the dual engineering of Stealth mRNA architectures and tissue-selective Lipid Nanoparticles (LNPs) to ensure prolonged functional expression in target tissues like the lungs, CNS, and endothelium.

Averna’s approach optimizes both chemistry and delivery:

Chemical Engineering: Incorporating sequence-engineered UTRs and specific base modifications (e.g., N-1-methylpseudouridine coupled with custom 5'-cap analogs like CleanCap® variants) to bypass endosomal TLR7/8 detection and prevent protein synthesis shutdown via PKR activation.
Organ-Targeted LNP Design: Utilizing Selective Organ Targeting (SORT) lipid chemistries (incorporating bi-functional ionizable lipids, helper lipids, and tissue-targeting ligands) that allow intravenous mRNA to bypass default liver uptake and concentrate in tissues requiring long-term protein production.

By reducing hepatic clearance and immune detection, Averna extends the functional translational half-life of non-integrating mRNA constructs from 24 hours to several weeks, opening a window for monthly or quarterly chronic administration without genetic modification.

Key Publications & Patents

Peer-Reviewed Reference: The foundational mechanics of tissue-tropic LNP targeting and immune-evasive nucleotide modifications are established in Cheng et al., "Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing" (Nature Nanotechnology, 2020) and Karikó et al., "Suppression of RNA recognition by Toll-like receptors" (Immunity, 2005).
Patent Citation: Averna’s delivery and expression architecture is protected under WO Patent Application 2023/154890 A1 ("Targeted lipid nanoparticle formulations and modified RNA constructs for persistent tissue expression"), describing proprietary lipid ratios and modified 3′ UTR elements that prevent deadenylation complexes from initiating early decay.

4) Tessera Therapeutics: Engineering Mobile Genetic Elements

To address these challenges, Tessera Therapeutics (founded by Flagship Pioneering) is pioneering Gene Writing™—a platform designed to achieve durable genetic cures using all-RNA, non-viral systems. By harnessing and engineering nature’s mobile genetic elements, Tessera transforms mRNA from a transient signal into a permanent, precise rewrite of the human genome.

Evolution’s Architecture: Harnessing Mobile Genetic Elements

Where traditional CRISPR-based tools evolved in bacteria as viral defense systems to sever DNA, mobile genetic elements (MGEs)—specifically non-long terminal repeat (non-LTR) retrotransposons—evolved across eukaryotic genomes for millions of years to write new DNA sequences. Human genomes, for instance, are composed of vast stretches of retrotransposon-derived sequences, such as Long Interspersed Element-1 (LINE-1).

Tessera’s Gene Writing™ platform systematically mines, engineers, and synthesizes these natural retrotransposase enzymes and synthetic MGEs. Instead of cutting both strands of the DNA double helix, engineered Gene Writer proteins use RNA templates to write new genetic instructions directly into the target genome.

Target-Primed Reverse Transcription (TPRT): The Biochemical Engine

At the core of Tessera’s technology is Target-Primed Reverse Transcription (TPRT), a four-step catalytic process through which retrotransposons permanently integrate genetic information:

By completing reverse transcription directly at the host DNA site, Gene Writers execute seamless genomic integration without creating free double-stranded breaks. This mechanism circumvents the genotoxic off-target translocations and p53-mediated DNA damage responses frequently triggered by classic Cas9 nucleases.

The Spectrum of Gene Writing Modalities

Tessera has structured its modular Gene Writing platform into three core capabilities based on the scale of genomic alteration required:

Gene Rewriters (Short Edits): Designed for single-nucleotide substitutions, precise insertions, and small deletions to correct point mutations directly.
Writing Exons (Exon-length Insertions): Replaces entire mutated exons at their native genomic locus with single-nucleotide precision.
Writing Whole Genes (Gene-length Insertions): Integrates multi-kilobase transgenes into designated genomic safe harbors or native loci, unlocking therapies for complex loss-of-function diseases and engineered cellular therapies.

Delivery Innovation: All-RNA LNPs and Targeted LNPs (tLNPs)

A defining advantage of Tessera's approach is that the entire Gene Writing system is delivered as all-RNA payloads inside lipid nanoparticles (LNPs):

Gene Writer mRNA: Encodes the engineered retrotransposase or RNA-guided writer enzyme.
Template RNA: Carries the therapeutic sequence, flanking regulatory motifs, and priming sequences.

Patent Citations, Peer-Reviewed & Conference Publications

EP4114940A4 / WO2020/047124A1 (Flagship Pioneering Innovations & Tessera Therapeutics): "Methods and compositions for modulating a genome." This foundational patent covers methods for genomic modulation using engineered mobile genetic element polypeptides and TPRT-based integration mechanisms.
WO2022/192863A1 (Flagship Pioneering Innovations & Tessera Therapeutics): "Engineered retrotransposable element proteins and systems for genome modulation." Outlines engineered variant retrotransposases optimized for sequence-specific single-strand nicking and reverse transcription in mammalian cells.
WO2024/192260A3 (Tessera Therapeutics, Inc.): "Untranslated region and poly(A) tail sequences for use in methods and compositions for genome modulation." Details artificial 5′ UTR, 3′ UTR, and poly(A) tail engineering strategies designed to maximize mRNA stability, translation kinetics, and fidelity during TPRT.
WO2025/096878A1 (Tessera Therapeutics, Inc.): "RNA for in vivo transfection with increased expression." Describes modified mRNA compositions and antibody-functionalized targeted LNPs (such as anti-CD8 tLNPs) for in vivo delivery to specific lymphocyte sub-populations.
Sickle Cell Disease In Vivo Correction (Blood, 2025): At the American Society of Hematology (ASH) Annual Meeting, Tessera presented preclinical data demonstrating in vivo correction of the $HBB$ E6V sickle mutation in hematopoietic stem cells (HSCs) using LNP-delivered RNA Gene Writers. Intravenous delivery achieved 74% editing efficiency in human $CD34^+$ cells ex vivo and maintained stable ~70% $HBB$ correction in long-term repopulating HSCs (LT-HSCs) across primary and secondary humanized mouse models and non-human primates (NHPs).
In Vivo CAR-T Generation (MDPI International Journal of Molecular Sciences, 2026): In "In Vivo CAR-T Therapies—A New Era of Programmable Immunity" (Pierini, S., 2026), Tessera's all-RNA tLNP platform was highlighted for its ability to deliver retrotransposon-based Gene Writers directly to T cells in vivo. Single-dose tLNP administration enabled stable genomic integration of anti-CD19 CAR constructs without viral vectors or ex vivo cell manipulation.

The Horizon of Persistent RNA Therapeutics

The transition from short-lived linear IVT mRNA vaccines to durable RNA-driven gene therapies marks the second major era of RNA medicine. By synthesizing innovations in novel RNA architecture, non-viral genomic integration, cell-free biomanufacturing, and tissue-tropic lipid encapsulation, companies like Typewriter, Addition, Averna, and Tessera are resolving the core trade-off between transient safety and persistent therapeutic efficacy.

As these platforms mature into clinical-stage assets, the future of gene therapy will increasingly diverge from viral vectors, while using the knowledge gained from those systems to improve the strategy. Whether through non-integrating RNA-encoded constructs that persist for weeks or transient mRNAs that permanently correct a single base pair in a cell, durable mRNA platforms represent the next frontier in curative genetic medicines.